Nucleotide-derived thrombin inhibitors: A new tool for an old issue

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 7, Issue 1, 2009, Pages 19-28

  Lancellotti, Stefano ^a   De Cristofaro, Raimondo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; ARC 183; ARGININE; BLOOD CLOTTING FACTOR 8; ENZYME INHIBITOR; HD 22; HEPARIN; NU 172; PEGAPTANIB; PROTEASE NEXIN I; PROTEINASE ACTIVATED RECEPTOR 1; RB 006; RB 007; THROMBIN; THROMBIN INHIBITOR; THROMBOMODULIN; TOGGLE 25; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTICOAGULANT AGENT; NUCLEOTIDE;

ANTICOAGULATION; BASE PAIRING; CELLULAR IMMUNITY; CLINICAL TRIAL; COST; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONFORMATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHARMACODYNAMICS; PRODUCT DEVELOPMENT; PROTEIN DEGRADATION; PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; UPREGULATION; X RAY DIFFRACTION; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN;

ANTICOAGULANTS; APTAMERS, NUCLEOTIDE; DRUG DESIGN; HUMANS; NUCLEOTIDES; THROMBIN;

EID: 64149118085     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152509787047658     Document Type: Review

References (96)

1. Burke, J.M.; Berzal-Herranz, A. In vitro selection and evolution of RNA: applications for catalytic RNA, molecular recognition, and drug discovery. FASEB J., 1993, 7, 106.
2. Bock, L.C.; Griffin, L.C.; Latham, J.A.; Vermaas, E.H.; Toole, J.J. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature, 1992, 355, 564.
3. Crawley, J.T.; Zanardelli, S.; Chion, C.K.; Lane, D.A. The central role of thrombin in hemostasis. J. Thromb. Haemost., 2007, 5(Suppl. 1), 95.
4. Di Cera, E. Thrombin as procoagulant and anticoagulant J. Thromb. Haemost., 2007, 5(Suppl. 1), 196.
5. Mann, K.G. Biochemistry and physiology of blood coagulation. Thromb. Haemost., 1999, 82, 165.
6. Mosesson, M.W. Fibrinogen and fibrin structure and functions. J. Thromb. Haemost., 2005, 3, 1894.
7. Esmon, C.T. The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity. J. Biol. Chem., 1979, 254, 964.
8. Fulcher, C.A.; Roberts, J.R.; Zimmerman, T.S. Thrombin proteolysis of purified factor viii procoagulant protein: correlation of activation with generation of a specific polypeptide. Blood, 1983, 61, 807.
9. Naito, K.; Fujikawa, K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J. Biol. Chem., 1991, 266, 7353.
10. Pedicord, D.L.; Seiffert, D.; Blat, Y. Feedback activation of factor XI by thrombin does not occur in plasma. Proc. Natl. Acad. Sci. USA, 2007, 104, 12855.
11. Lundblad, R.L.; White, G.C., 2nd. The interaction of thrombin with blood platelets. Platelets, 2005, 16, 373.
12. Vu, T.K.; Hung, D.T.; Wheaton, V.I.; Coughlin, S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell, 1991, 64, 1057.
13. Kahn, M.L.; Zheng, Y.W.; Huang, W.; Bigornia, V.; Zeng, D.; Moff, S.; Farese, R. V., Jr.; Tam, C.; Coughlin, S.R. A dual thrombin receptor system for platelet activation. Nature, 1998, 394, 690.
14. Adam, F.; Guillin, M.C.; Jandrot-Perrus, M. Glycoprotein Ib-mediated platelet activation. A signalling pathway triggered by thrombin. Eur. J. Biochem., 2003, 270, 2959.
15. De Candia, E.; Hall, S.W.; Rutella, S.; Landolfi, R.; Andrews, R.K.; De Cristofaro, R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J. Biol. Chem., 2001, 276, 4692.
16. Esmon, C.T. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J. Biol. Chem., 1989, 264, 4743.
17. Bajzar, L.; Manuel, R.; Nesheim, M.E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J. Biol. Chem., 1995, 270, 14477.
18. Coughlin, S.R. Thrombin signalling and protease-activated receptors. Nature, 2000, 407, 258.
19. Soifer, S.J.; Peters, K.G.; O'Keefe, J.; Coughlin, S.R. Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development. Am. J. Pathol., 1994, 144, 60.
20. Hattori, R.; Hamilton, K.K.; Fugate, R.D.; McEver, R.P.; Sims, P.J. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J. Biol. Chem., 1989, 264, 7768.
21. Lum, H.; Malik, A.B. Regulation of vascular endothelial barrier function. Am. J. Physiol., 1994, 267, L223.
22. Bar-Shavit, R.; Kahn, A.; Wilner, G.D.; Fenton, J.W., 2nd. Monocyte chemotaxis: stimulation by specific exosite region in thrombin. Science, 1983, 220, 728.
23. Bar-Shavit, R.; Kahn, A.J.; Mann, K.G.; Wilner, G.D. Identification of a thrombin sequence with growth factor activity on macrophages. Proc. Natl. Acad. Sci. USA, 1986, 83, 976.
24. Tesfamariam, B.; Allen, G.T.; Normandin, D.; Antonaccio, M.J. Involvement of the "tethered ligand" receptor in thrombin-induced endothelium-mediated relaxations. Am. J. Physiol., 1993, 265, H1744.
25. Tsopanoglou, N.E.; Maragoudakis, M.E. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors. J. Biol. Chem., 1999, 274, 23969.
26. Festoff, B.W.; Smirnova, I.V.; Ma, J.; Citron, B.A. Thrombin, its receptor and protease nexin I, its potent serpin, in the nervous system. Semin. Thromb. Hemost., 1996, 22, 267.
27. Bode, W.; Turk, D.; Karshikov, A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci., 1992, 1, 426.
28. Bode, W. The structure of thrombin, a chameleon-like proteinase. J. Thromb. Haemost., 2005, 3, 2379.
29. Lane, D.A.; Philippou, H.; Huntington, J.A. Directing thrombin. Blood, 2005, 106, 2605.
30. Bagdy, D.; Barabas, E.; Graf, L.; Petersen, T.E.; Magnusson, S. Hirudin. Methods Enzymol., 1976, 45, 669.
31. Strube, K.H.; Kroger, B.; Bialojan, S.; Otte, M.; Dodt, J. Isolation, sequence analysis, and cloning of haemadin. An anticoagulant peptide from the Indian leech. J. Biol. Chem., 1993, 268, 8590.
32. Friedrich, T.; Kroger, B.; Bialojan, S.; Lemaire, H.G.; Hoffken, H.W.; Reuschenbach, P.; Otte, M.; Dodt, J. A Kazal-type inhibitor with thrombin specificity from Rhodnius prolixus. J. Biol. Chem., 1993, 268, 16216.
33. Rose, T.; Di Cera, E. Three-dimensional modeling of thrombin-fibrinogen interaction. J. Biol. Chem., 2002, 277, 18875.
34. Pechik, I.; Madrazo, J.; Mosesson, M.W.; Hernandez, I.; Gilliland, G.L.; Medved, L. Crystal structure of the complex between thrombin and the central "E" region of fibrin. Proc. Natl. Acad. Sci. USA, 2004, 101, 2718.
35. Mathews, II.; Padmanabhan, K.P.; Ganesh, V.; Tulinsky, A.; Ishii, M.; Chen, J.; Turck, C.W.; Coughlin, S.R.; Fenton, J.W., 2nd Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry, 1994, 33, 3266.
36. Esmon, C.T.; Lollar, P. Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII. J. Biol. Chem., 1996, 271, 13882.
37. Myles, T.; Yun, T.H.; Leung, L.L. Structural requirements for the activation of human factor VIII by thrombin. Blood, 2002, 100, 2820.
38. Fuentes-Prior, P.; Iwanaga, Y.; Huber, R.; Pagila, R.; Rumennik, G.; Seto, M.; Morser, J.; Light, D. R.; Bode, W. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature, 2000, 404, 518.
39. Sheehan, J.P.; Wu, Q.; Tollefsen, D.M.; Sadler, J.E. Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity. J. Biol. Chem., 1993, 268, 3639.
40. Stone, S.R.; Braun, P.J.; Hofsteenge, J. Identification of regions of alpha-thrombin involved in its interaction with hirudin. Biochemistry, 1987, 26, 4617.
41. Rydel, T.J.; Tulinsky, A.; Bode, W.; Huber, R. Refined structure of the hirudin-thrombin complex. J. Mol. Biol., 1991, 221, 583.
42. Carter, W.J.; Cama, E.; Huntington, J.A. Crystal structure of thrombin bound to heparin. J. Biol. Chem., 2005, 280, 2745.
43. Li, W.; Johnson, D.J.; Esmon, C.T.; Huntington, J.A. Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat. Struct. Mol. Biol., 2004, 11, 857.
44. Segers, K.; Dahlback, B.; Bock, P.E.; Tans, G.; Rosing, J.; Nicolaes, G.A. The role of thrombin exosites I and II in the activation of human coagulation factor V. J. Biol. Chem., 2007, 282, 33915.
45. De Cristofaro, R.; De Candia, E.; Landolfi, R.; Rutella, S.; Hall, S.W. Structural and functional mapping of the thrombin domain involved in the binding to the platelet glycoprotein Ib. Biochemistry, 2001, 40, 13268.
46. Celikel, R.; McClintock, R.A.; Roberts, J.R.; Mendolicchio, G.L.; Ware, J.; Varughese, K.I.; Ruggeri, Z.M. Modulation of alphathrombin function by distinct interactions with platelet glycoprotein Ibalpha. Science, 2003, 301, 218.
47. De Cristofaro, R.; De Filippis, V. Interaction of the 268-282 region of glycoprotein Ibalpha with the heparin-binding site of thrombin inhibits the enzyme activation of factor VIII. Biochem. J., 2003, 373, 593.
48. Gold, L.; Brown, D.; He, Y.; Shtatland, T.; Singer, B.S.; Wu, Y. From oligonucleotide shapes to genomic SELEX: novel biological regulatory loops. Proc. Natl. Acad. Sci. USA, 1997, 94, 59.
49. Lee, J.H.; Canny, M.D.; De Erkenez, A.; Krilleke, D.; Ng, Y.S.; Shima, D.T.; Pardi, A.; Jucker, F.A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc. Natl. Acad. Sci. USA, 2005, 102, 18902.
50. Ruckman, J.; Green, L.S.; Beeson, J.; Waugh, S.; Gillette, W.L.; Henninger, D.D.; Claesson-Welsh, L.; Janjic, N. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular-endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem., 1998, 273, 20556.
51. Gragoudas, E.S.; Adamis, A.P.; Cunningham, E.T., Jr.; Feinsod, M.; Guyer, D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med., 2004, 351, 2805.
52. Moshfeghi, A.A.; Puliafito, C.A. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. Expert. Opin. Investig. Drugs, 2005, 14, 671.
53. Gold, L. Oligonucleotides as research, diagnostic, and therapeutic agents. J. Biol. Chem., 1995, 270, 13581.
54. Jellinek, D.; Green, L.S.; Bell, C.; Lynott, C.K.; Gill, N.; Vargeese, C.; Kirschenheuter, G.; McGee, D.P.; Abesinghe, P.; Pieken, W.A.; et al. Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry, 1995, 34, 11363.
55. Kato, Y.; Minakawa, N.; Komatsu, Y.; Kamiya, H.; Ogawa, N.; Harashima, H.; Matsuda, A. New NTP analogs: the synthesis of 4′-thioUTP and 4′-thioCTP and their utility for SELEX. Nucleic Acids Res., 2005, 33, 2942.
56. Uhlmann, E.; Peyman, A.; Ryte, A.; Schmidt, A.; Buddecke, E. Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression. Methods Enzymol., 2000, 313, 268.
57. Burmeister, P.E.; Lewis, S.D.; Silva, R.F.; Preiss, J.R.; Horwitz, L.R.; Pendergrast, P.S.; McCauley, T.G.; Kurz, J.C.; Epstein, D M.; Wilson, C.; Keefe, A.D. Direct in vitro selection of a 2′-O-methyl aptamer to VEGF. Chem. Biol., 2005, 12, 25.
58. Lapham, J.; Yu, Y.T.; Shu, M.D.; Steitz, J.A.; Crothers, D.M. The position of site-directed cleavage of RNA using RNase H and 2′-Omethyl oligonucleotides is dependent on the enzyme source. RNA, 1997, 3, 950.
59. Richardson, F.C.; Kuchta, R.D.; Mazurkiewicz, A.; Richardson, K.A. Polymerization of 2′-fluoro- and 2′-O-methyl-dNTPs by human DNA polymerase alpha, polymerase gamma, and primase. Biochem. Pharmacol., 2000, 59, 1045.
60. Ikebukuro, K.; Yoshida, W.; Noma, T.; Sode, K. Analysis of the evolution of the thrombin-inhibiting DNA aptamers using a genetic algorithm. Biotechnol. Lett., 2006, 28, 1933.
61. Ikebukuro, K.; Okumura, Y.; Sumikura, K.; Karube, I. A novel method of screening thrombin-inhibiting DNA aptamers using an evolution-mimicking algorithm. Nucleic Acids Res., 2005, 33, e108.
62. Noma, T.; Ikebukuro, K. Aptamer selection based on inhibitory activity using an evolution-mimicking algorithm. Biochem. Biophys. Res. Commun., 2006, 347, 226.
63. Martino, L.; Virno, A.; Randazzo, A.; Virgilio, A.; Esposito, V.; Giancola, C.; Bucci, M.; Cirino, G.; Mayol, L. A new modified thrombin binding aptamer containing a 5′-5′ inversion of polarity site. Nucleic Acids Res., 2006, 34, 6653.
64. Smirnov, I.V.; Kotch, F.W.; Pickering, I.J.; Davis, J.T.; Shafer, R.H. Pb EXAFS studies on DNA quadruplexes: identification of metal ion binding site. Biochemistry, 2002, 41, 12133.
65. Padmanabhan, K.; Padmanabhan, K.P.; Ferrara, J.D.; Sadler, J.E.; Tulinsky, A. The structure of alpha-thrombin inhibited by a 15-mer single-stranded DNA aptamer. J. Biol. Chem., 1993, 268, 17651.
66. Kretz, C.A.; Stafford, A.R.; Fredenburgh, J.C.; Weitz, J.I. HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase. J. Biol. Chem., 2006, 281, 37477.
67. Paborsky, L.R.; McCurdy, S.N.; Griffin, L.C.; Toole, J.J.; Leung, L.L. The single-stranded DNA aptamer-binding site of human thrombin. J. Biol. Chem., 1993, 268, 20808.
68. He, G.X.; Krawczyk, S.H.; Swaminathan, S.; Shea, R.G.; Dougherty, J.P.; Terhorst, T.; Law, V.S.; Griffin, L.C.; Coutre, S.; Bischofberger, N. N2- and C8-substituted oligodeoxynucleotides with enhanced thrombin inhibitory activity in vitro and in vivo. J. Med. Chem., 1998, 41, 2234.
69. He, G.X.; Williams, J.P.; Postich, M.J.; Swaminathan, S.; Shea, R.G.; Terhorst, T.; Law, V.S.; Mao, C.T.; Sueoka, C.; Coutre, S.; Bischofberger, N. In vitro and in vivo activities of oligodeoxynucleotide-based thrombin inhibitors containing neutral formacetal linkages. J. Med. Chem., 1998, 41, 4224.
70. Pagano, B.; Martino, L.; Randazzo, A.; Giancola, C. Stability and binding properties of a modified thrombin binding aptamer. Biophys. J., 2008, 94, 562.
71. Nimjee, S.M.; Rusconi, C.P.; Sullenger, B.A. Aptamers: an emerging class of therapeutics. Annu. Rev. Med., 2005, 56, 555.
72. Hianik, T.; Ostatna, V.; Sonlajtnerova, M.; Grman, I. Influence of ionic strength, pH and aptamer configuration for binding affinity to thrombin. Bioelectrochemistry, 2007, 70, 127.
73. McCauley, T.G.; Hamaguchi, N.; Stanton, M. Aptamer-based biosensor arrays for detection and quantification of biological macromolecules. Anal. Biochem., 2003, 319, 244.
74. Kelly, J.A.; Feigon, J.; Yeates, T.O. Reconciliation of the X-ray and NMR structures of the thrombin-binding aptamer d(GGTT GGTGTGGTTGG). J. Mol. Biol., 1996, 256, 417.
75. Najafi-Shoushtari, S.H.; Famulok, M. DNA aptamer-mediated regulation of the hairpin ribozyme by human alpha-thrombin. Blood Cells Mol. Dis., 2007, 38, 19.
76. Macaya, R.F.; Schultze, P.; Smith, F.W.; Roe, J.A.; Feigon, J. Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. Proc. Natl. Acad. Sci. USA, 1993, 90, 3745.
77. Wang, K.Y.; McCurdy, S.; Shea, R.G.; Swaminathan, S.; Bolton, P.H. A DNA aptamer which binds to and inhibits thrombin exhibits a new structural motif for DNA. Biochemistry, 1993, 32, 1899.
78. Guschlbauer, W.; Chantot, J.F.; Thiele, D. Four-stranded nucleic acid structures 25 years later: from guanosine gels to telomer DNA. J. Biomol. Struct. Dyn., 1990, 8, 491.
79. Rhodes, D.; Giraldo, R. Telomere structure and function. Curr. Opin. Struct. Biol., 1995, 5, 311.
80. Tasset, D.M.; Kubik, M.F.; Steiner, W. Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. J. Mol. Biol., 1997, 272, 688.
81. Leung, L.L. Application of combinatorial libraries and protein engineering to the discovery of novel anti-thrombotic drugs. Thromb. Haemost., 1995, 74, 373.
82. De Cristofaro, R.; De Candia, E.; Rutella, S.; Weitz, J.I. The Asp(272)-Glu(282) region of platelet glycoprotein Ibalpha interacts with the heparin-binding site of alpha-thrombin and protects the enzyme from the heparin-catalyzed inhibition by antithrombin III. J. Biol. Chem., 2000, 275, 3887.
83. Lovely, R.S.; Moaddel, M.; Farrell, D.H. Fibrinogen gamma' chain binds thrombin exosite II. J. Thromb. Haemost., 2003, 1, 124.
84. White, R.; Rusconi, C.; Scardino, E.; Wolberg, A.; Lawson, J.; Hoffman, M.; Sullenger, B. Generation of species cross-reactive aptamers using "toggle" SELEX. Mol. Ther., 2001, 4, 567.
85. Hayakawa, Y.; Hayashi, T.; Lee, J.; Srisomporn, P.; Maeda, M.; Ozawa, T.; Sakuragawa, N. Inhibition of thrombin by sulfated polysaccharides isolated from green algae. Biochim. Biophys. Acta, 2000, 1543, 86.
86. Reyderman, L.; Stavchansky, S. Pharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in rats. Pharm. Res., 1998, 15, 904.
87. Dougan, H.; Lyster, D.M.; Vo, C.V.; Stafford, A.; Weitz, J.I.; Hobbs, J.B. Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. Nucl. Med. Biol., 2000, 27, 289.
88. Richardson, F.C.; Tennant, B.C.; Meyer, D.J.; Richardson, K.A.; Mann, P.C.; McGinty, G.R.; Wolf, J.L.; Zack, P.M.; Bendele, R.A. An evaluation of the toxicities of 2′-fluorouridine and 2′-fluorocytidine-HCl in F344 rats and woodchucks (Marmota monax). Toxicol. Pathol., 1999, 27, 607.
89. Tucker, C.E.; Chen, L.S.; Judkins, M.B.; Farmer, J.A.; Gill, S.C.; Drolet, D.W. Detection and plasma pharmacokinetics of an antivascular endothelial growth factor oligonucleotide-aptamer (NX 1838) in rhesus monkeys. J. Chromatogr. B Biomed. Sci. Appl., 1999, 732, 203.
90. Rusconi, C.P.; Scardino, E.; Layzer, J.; Pitoc, G.A.; Ortel, T.L.; Monroe, D.; Sullenger, B.A. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature, 2002, 419, 90.
91. Chan, M.Y.; Rusconi, C.P.; Alexander, J.H.; Tonkens, R.M.; Harrington, R.A.; Becker, R.C. A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J. Thromb. Haemost., 2008, 6, 789.
92. Bartel, D.P.; Zapp, M.L.; Green, M.R.; Szostak, J.W. HIV-1 Rev regulation involves recognition of non-Watson-Crick base pairs in viral RNA. Cell, 1991, 67, 529.
93. Tuerk, C.; MacDougal-Waugh, S. In vitro evolution of functional nucleic acids: high-affinity RNA ligands of HIV-1 proteins. Gene, 1993, 137, 33.
94. Boncler, M.A.; Koziolkiewicz, M.; Watala, C. Aptamer inhibits degradation of platelet proteolytically activatable receptor, PAR-1, by thrombin. Thromb. Res., 2001, 104, 215.
95. Li, W.X.; Kaplan, A.V.; Grant, G.W.; Toole, J.J.; Leung, L.L. A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. Blood, 1994, 83, 677.
96. Griffin, L.C.; Tidmarsh, G.F.; Bock, L.C.; Toole, J.J.; Leung, L.L. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood, 1993, 81, 3271.